Attogen is leading the way in the fight against cancer, with a new breed of monoclonal antibodies and peptides that bind to altered protein forms associated with tumors. These highly selective antibodies can distinguish the altered protein forms from their counterparts of wild type (healthy) protein forms.

In collaboration with leading research institutions and drug developers, Attogen is leveraging its technology platform to generate isoform-specific antibodies and peptides to validated cancer targets. These are useful as diagnostic biomarkers, therapeutic agents, and drug discovery tools.

Attogen’s programs in metastasis, angiogenesis, and cancer vaccine offer hope for a world in which cancer survival rates may someday approach those of most common infectious diseases.

Attogen Biomedical Research (ABR) is a division of Attogen, Inc.
ABR provides contract services for:

• Monoclonal antibody generation (mouse and rabbit) 
• Antibody Epitope Mapping 
• Multiplexed Biomarker Detection - assay development

Attogen Biomedical Research provides specialty antibody reagents, which are new and hard-to-find from large catalog companies.